News & Trends - Medical Technology

Innovative method to regenerate articular cartilage for patient surgery

Health Industry Hub | June 29, 2020 |
[Total: 1    Average: 5/5]

MedTech News: Recipient of the Royal Australasian College of Surgeons (RACS) Senior Lecturer Fellowship, Associate Professor Claudia Di Bella, and her research team at BioFab3D, trademarked a ground-breaking method of stem cell transplantation.

BioFab3D is Australia’s first robotics and biomedical engineering centre within a hospital. Researchers, clinicians, engineers and industry partners work to build biological structures such as cartilage, muscle, bone, nerves and organs – almost anything that requires repair through disease and physical trauma.

St Vincent’s Hospital Melbourne has partnered with four universities – the University of Melbourne, RMIT University, Swinburne University of Technology and University of Wollongong – to create a unique hub for
innovation and translation.

Associate Professor Di Bella’s team is regenerating articular cartilage by using advanced biofabrication techniques and technology with the use of stem cells that are printed within a gelatinous scaffold and then cultured in 3D. The cartilage project is the largest program at BioFab3D.

The typical pathway for a stem cell transplant procedure involves taking
cells from the patient, then printing and growing them in the lab while the patient waits at home for the cells to do their work and create tissue. The third and final stage is reimplantation into the patient.

The BioFab3D team is hoping to eliminate the second stage of this process because it’s a big obstacle to Therapeutic Goods Administration (TGA) approval, or to any process that involves tissue engineering.

The revolutionary new procedure that the team hopes to implement will require one simple step. It will take the patient’s own stem cells, then mix them with a scaffold so they have somewhere to grow before putting them back into the same patient to regenerate their own cartilage.

The product has been trademarked, registered and seeking a pathway towards commercialisation. A clinical trial will also commence shortly.


About the author

About the author

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nam luctus finibus scelerisque. Nunc bibendum ipsum sed augue fringilla fringilla. Nullam at consectetur leo. Praesent viverra rutrum porta. Quisque vitae mi vel purus vulputate tincidunt. Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos. Suspendisse et mi quis nisi rhoncus feugiat at ac tellus. Sed aliquam sodales nulla ac auctor. Sed pretium lobortis purus accumsan ullamcorper. Phasellus sodales vel odio in lobortis. Duis maximus sagittis bibendum. Interdum et malesuada fames ac ante ipsum primis in faucibus. Nunc dictum tincidunt ipsum in vestibulum. Donec ut sem consectetur, aliquam quam vitae, pharetra orci. Nam egestas non velit eu rhoncus. Duis congue neque non lacus tincidunt porta. Vestibulum ultricies pulvinar sem, molestie congue dui aliquet non.
  • Ut imperdiet leo id lorem fermentum consectetur.
  • Ut vitae orci et dui varius tincidunt.
  • Ut id magna non libero vestibulum pharetra ac faucibus nulla.
Aliquam erat volutpat. Vestibulum vitae varius diam. Nulla eget congue ante. Nunc ullamcorper sagittis augue vel dictum. Mauris finibus nibh ut pulvinar auctor. Vestibulum ut faucibus nisi. Orci varius natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Quisque porta tortor ac justo malesuada elementum. Nulla tellus ante, cursus nec ex sit amet, suscipit bibendum arcu. Duis posuere orci dui, et mollis enim dictum at. Sed ullamcorper, sapien ut vulputate viverra, sem purus porttitor tellus, nec mattis mauris ligula sed risus. Nulla sagittis id ipsum eu mattis. Link to full profile

News & Trends - Medical Technology

MedTech News - Private health insurer looking to invest in Australian private hospitals

Private health insurer looking to invest in Australian private hospitals

Health Industry Hub | July 15, 2020 |

MedTech News: In a recent opinion piece Dr Bill Coote, former AMA Secretary General and former Director of the Medicare […]

More


News & Trends - Pharmaceuticals

Pharma News - Merck Australia supports the first Australian-developed COVID-19 vaccine - Sypharma and Vaxine

Merck Australia supports the first Australian-developed COVID-19 vaccine

Health Industry Hub | July 15, 2020 |

Pharma News: Sypharma, an Australian biopharmaceutical formulation company, announced manufacturing of COVAX-19 and Advax adjuvant for Covid-19 in partnership with […]

More


News & Trends - Pharmaceuticals

Pharma News - Precision prescribing to combat Australia’s expected surge in mental illness

Precision prescribing to combat Australia’s expected surge in mental illness

Health Industry Hub | July 15, 2020 |

Pharma News: COVID-19 social isolation, familial and community disconnection, shock, job loss and health fears create the perfect storm for […]

More


Medical

Medical Pharma Biotech MedTech - $47M accelerator program for MedTech, Biotech and Pharma sectors in diabetes and cardiovascular disease

$47M accelerator program for MedTech, Biotech and Pharma sectors in diabetes and cardiovascular disease

Health Industry Hub | July 15, 2020 |

Medical News: The operation of the Australian Government’s $47 million Targeted Translation Research Accelerator (TTRA) initiative for diabetes and cardiovascular […]

More